Movement disorders HIT publishes interactive pathway for Duodopa treatment
The Movement Disorders Health Integration Team has published its first interactive pathway which describes the services and support patients can expect when they are being considered for treatment with Duodopa.
24th January 2019
The Movement Disorders Health Integration Team is pleased to publish its first interactive pathway (PDF) which describes the services and support patients can expect when they are being considered for treatment with Duodopa.
Duodopa is a gel that contains levodopa and carbidopa, for treatment of movement disorders. This pathway is designed to help health professionals, people with movement disorders and those close to them to navigate the different services available to support them. It aims to help clinicians understand the process for referral, assessment and decision making.
It is the first in a series of interactive pathways that the team is working on, to help patients and local clinicians better understand what to expect from different aspects of movement disorders care.